In this slide show we highlight some of the top news from the past year on genetic testing for cancer, including gene signatures for identifying different sub-types of breast cancer, the influence of genetics on RCC outcomes, and the utility of liquid biopsies.
Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.
A new study has revealed that the amount of iron in the blood affects the amount of the Scribble protein, which appears to control receptors that create new red blood cells.
Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.
Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.
The PAM50 risk of recurrence score can improve the prediction of recurrence at 10 years in postmenopausal patients with HR-positive early breast cancer.
In this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some lethal cancers.
Researchers have made a discovery linking chromosomal instability to cancer metastasis through chronic inflammation, a first in identifying a widespread genomic driver of metastasis.
Do you know which molecular markers signify poor-risk disease in AML? And how about what makes AML a challenging disease to manage in older adult patients? Test your knowledge in our latest quiz.
The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.
Know when to change targeted therapies in patients with progressive lung cancer? How about appropriate patient criteria for segmentectomy or wedge resection? Test your knowledge in our latest quiz.
Immunochemotherapy should remain the standard induction approach for patients with high-risk follicular lymphoma.
A 46-year-old man presents with a thyroid mass, and a biopsy is obtained. What is your diagnosis?
Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival over ADT alone in metastatic hormone-sensitive prostate cancer patients with high-volume disease.